[Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]]
Standard
[Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]]. / Luger, Thomas; Reusch, Michael; Reich, Kristian; Augustin, Matthias; Sterry, Wolfram.
in: J DTSCH DERMATOL GES, Jahrgang 7, Nr. 4, 4, 2009, S. 291-292.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
Luger, T, Reusch, M, Reich, K, Augustin, M & Sterry, W 2009, '[Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]]', J DTSCH DERMATOL GES, Jg. 7, Nr. 4, 4, S. 291-292. <http://www.ncbi.nlm.nih.gov/pubmed/19500192?dopt=Citation>
APA
Luger, T., Reusch, M., Reich, K., Augustin, M., & Sterry, W. (2009). [Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]]. J DTSCH DERMATOL GES, 7(4), 291-292. [4]. http://www.ncbi.nlm.nih.gov/pubmed/19500192?dopt=Citation
Vancouver
Luger T, Reusch M, Reich K, Augustin M, Sterry W. [Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]]. J DTSCH DERMATOL GES. 2009;7(4):291-292. 4.
Bibtex
@article{1b7cc6f6e9c24295be2f8f4def4f8a40,
title = "[Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]]",
author = "Thomas Luger and Michael Reusch and Kristian Reich and Matthias Augustin and Wolfram Sterry",
year = "2009",
language = "Deutsch",
volume = "7",
pages = "291--292",
journal = "J DTSCH DERMATOL GES",
issn = "1610-0379",
publisher = "Wiley-Blackwell",
number = "4",
}
RIS
TY - JOUR
T1 - [Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]]
AU - Luger, Thomas
AU - Reusch, Michael
AU - Reich, Kristian
AU - Augustin, Matthias
AU - Sterry, Wolfram
PY - 2009
Y1 - 2009
M3 - SCORING: Zeitschriftenaufsatz
VL - 7
SP - 291
EP - 292
JO - J DTSCH DERMATOL GES
JF - J DTSCH DERMATOL GES
SN - 1610-0379
IS - 4
M1 - 4
ER -
